Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice

Journal of Proteome Research

Volumn 9, Issue 1, 2010, Pages 404-412

  Joyner, P Matthew ^a   Matheke, Ronni M ^a   Smith, Lindsey M ^a   Cichewicz, Robert H ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Disease models; Huntington's disease; Metabolism; Metabolomics; Neurodegenerative disease; Phenotypic profiling; Yeast

Indexed keywords

ACETIC ACID; ALANINE; BIOLOGICAL MARKER; GALACTOSE; GLUTAMINE; GLYCEROL; HISTIDINE; HUNTINGTIN; PROLINE; SUCCINIC ACID; THREONINE; TREHALOSE; VALINE;

AMINO TERMINAL SEQUENCE; ARTICLE; HUMAN; HUNTINGTON CHOREA; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; TOXICITY TESTING; TRANSGENIC MOUSE;

AMINO ACIDS; ANIMALS; CARBOHYDRATE METABOLISM; CHI-SQUARE DISTRIBUTION; FOURIER ANALYSIS; HUMANS; HUNTINGTON DISEASE; METABOLOME; MICE; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; NUCLEAR PROTEINS; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION;

MUS; MUS MUSCULUS;

EID: 73649095908     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900734g     Document Type: Article

References (54)

1. Imarisio, S.; Carmichael, J.; Korolchuk, V.; Chen, C.-W.; Saiki, S.; Rose, C.; Krishna, G.; Davies, J. E.; Ttofi, E.; Underwood, B. R.; Rubinsztein, D. C. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 2008, 412 (2), 191-209.
2. Walker, F. O. Huntington's disease. Lancet 2007, 369 (9557), 218-228.
3. Langbehn, D. R.; Hayden, M. R.; Paulsen, J. S. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Am. J. Med. Genet., Part B 2009, DOI: 10.1002/ajmg.b.30992.
4. Shao, J.; Diamond, M. I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 2007, 16 (R2), R115-123.
5. Yang, S.-H.; Cheng, P.-H.; Banta, H.; Piotrowska-Nitsche, K.; Yang, J.-J.; Cheng, E. C. H.; Snyder, B.; Larkin, K.; Liu, J.; Orkin, J.; Fang, Z.-H.; Smith, Y.; Bachevalier, J.; Zola, S. M.; Li, S.-H.; Li, X.-J.; Chan, A. W. S. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008, 453 (7197), 921-924.
6. Menalled, L.; El-Khodor, B. F.; Patry, M.; Suárez-Fariñas, M.; Orenstein, S. J.; Zahasky, B.; Leahy, C.; Wheeler, V.; Yang, X. W.; MacDonald, M.; Morton, A. J.; Bates, G.; Leeds, J.; Park, L.; Howland, D.; Signer, E.; Tobin, A.; Brunner, D. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 2009, 35 (3), 319-336.
7. Van Raamsdonk, J. M.; Warby, S. C.; Hayden, M. R. Selective degeneration in YAC mouse models of Huntington disease. Brain Res. Bull. 2007, 72 (2-3), 124-131.
8. Masuda, N.; Peng, Q.; Li, Q.; Jiang, M.; Liang, Y.; Wang, X.; Zhao, M.; Wang, W.; Ross, C. A.; Duan, W. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol. Dis. 2008, 30 (3), 293-302.
9. Diekmann, H.; Anichtchik, O.; Fleming, A.; Futter, M.; Goldsmith, P.; Roach, A.; Rubinsztein, D. C. Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish. J. Neurosci. 2009, 29 (5), 1343-1349.
10. Schiffer, N. W.; Broadley, S. A.; Hirschberger, T.; Tavan, P.; Kretzschmar, H. A.; Giese, A.; Haass, C.; Hartl, F. U.; Schmid, B. Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. J. Biol. Chem. 2007, 282 (12), 9195-9203.
11. Lumsden, A. L.; Henshall, T. L.; Dayan, S.; Lardelli, M. T.; Richards, R. I. Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum. Mol. Genet. 2007, 16 (16), 1905-1920.
12. Jackson, G. R.; Salecker, I.; Dong, X.; Yao, X.; Arnheim, N.; Faber, P. W.; MacDonald, M. E.; Zipursky, S. L. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998, 21 (3), 633-642.
13. Branco, J.; Al-Ramahi, I.; Ukani, L.; Perez, A. M.; Fernandez-Funez, P.; Rincon-Limas, D.; Botas, J. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. Hum. Mol. Genet. 2008, 17 (3), 376-390.
14. Wolfgang, W. J.; Miller, T. W.; Webster, J. M.; Huston, J. S.; Thompson, L. M.; Marsh, J. L.; Messer, A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (32), 11563-11568.
15. Ravikumar, B.; Vacher, C.; Berger, Z.; Davies, J. E.; Luo, S.; Oroz, L. G.; Scaravilli, F.; Easton, D. F.; Duden, R.; O'Kane, C. J.; Rubinsztein, D. C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36 (6), 585-595.
16. Jeong, H.; Then, F.; Melia Jr, T. J.; Mazzulli, J. R.; Cui, L.; Savas, J. N.; Voisine, C.; Paganetti, P.; Tanese, N.; Hart, A. C.; Yamamoto, A.; Krainc, D. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137 (1), 60-72.
17. Faber, P. W.; Voisine, C.; King, D. C.; Bates, E. A.; Hart, A. C. Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (26), 17131-17136.
18. Faber, P. W.; Alter, J. R.; MacDonald, M. E.; Hart, A. C. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (1), 179-184.
19. Satyal, S. H.; Schmidt, E.; Kitagawa, K.; Sondheimer, N.; Lindquist, S.; Kramer, J. M.; Morimoto, R. I. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (11), 5750-5755.
20. Desai, U. A.; Pallos, J.; Ma, A. A. K.; Stockwell, B. R.; Thompson, L. M.; Marsh, J. L.; Diamond, M. I. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum. Mol. Genet. 2006, 15 (13), 2114-2124.
21. Igarashi, S.; Morita, H.; Bennett, K. M.; Tanaka, Y.; Engelender, S.; Peters, M. F.; Cooper, J. K.; Wood, J. D.; Sawa, A.; Ross, C. A. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 2003, 14 (4), 565-568.
22. Subramaniam, S.; Sixt, K. M.; Barrow, R.; Snyder, S. H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324 (5932), 1327-1330.
23. Meriin, A. B.; Zhang, X.; He, X.; Newnam, G. P.; Chernoff, Y. O.; Sherman, M. Y. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J. Cell Biol. 2002, 157 (6), 997-1004.
24. Giorgini, F.; Muchowski, P. J., Exploiting Yeast Genetics to Inform Therapeutic Strategies for Huntington's Disease. In Yeast Functional Genomics and Proteomics; Stagljar, I., Ed.; Humana Press: New York, 2009; Vol. 548, pp 161-174.
25. Krobitsch, S.; Lindquist, S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (4), 1589-1594.
26. Gil, J. M.; Rego, A. C. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res. Rev. 2009, 59 (2), 410-431.
27. Li, J. Y.; Popovic, N.; Brundin, P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005, 2 (3), 447-464.
28. Wang, W.; Duan, W.; Igarashi, S.; Morita, H.; Nakamura, M.; Ross, C. A. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol. Dis. 2005, 20 (2), 500-508.
29. Sarkar, S.; Perlstein, E. O.; Imarisio, S.; Pineau, S.; Cordenier, A.; Maglathlin, R. L.; Webster, J. A.; Lewis, T. A.; O'Kane, C. J.; Schreiber, S. L.; Rubinsztein, D. C. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 2007, 3 (6), 331-338.
30. Zhang, X.; Smith, D. L.; Meriin, A. B.; Engemann, S.; Russel, D. E.; Roark, M.; Washington, S. L.; Maxwell, M. M.; Marsh, J. L.; Thompson, L. M.; Wanker, E. E.; Young, A. B.; Housman, D. E.; Bates, G. P.; Sherman, M. Y.; Kazantsev, A. G. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (3), 892-897.
31. Outeiro, T. F.; Giorgini, F. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Biotechnol. J. 2006, 1 (3), 258-269.
32. Williams, R. B.; Gutekunst, W. R.; Joyner, P. M.; Duan, W.; Li, Q.; Ross, C. A.; Williams, T. D.; Cichewicz, R. H. Bioactivity profiling with parallel mass spectrometry reveals an assemblage of green tea metabolites affording protection against human huntingtin and α-synuclein toxicity. J. Agric. Food Chem. 2007, 55 (23), 9450-9456.
33. Jolliffe, I. T. Principal Component Analysis; Springer-Verlag: New York, 2002.
34. Tsang, T. M.; Haselden, J. N.; Holmes, E. Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease. Neurochem. Res. 2009, 34 (7), 1261-1271.
35. Greenacre, M. Correspondence analysis in medical research. Stat. Methods Med. Res. 1992, 1 (1), 97-117.
36. Greenacre, M., Correspondence analysis in practice, 2nd ed.; Chapman & Hall/CRC Taylor & Francis Group: Boca Raton, FL, 2007.
37. Greenacre, M. J.; Degos, L. Correspondence analysis of HLA gene frequency data from 124 population samples. Am. J. Hum. Genet. 1977, 1 (1), 60-75.
38. Weljie, A. M.; Newton, J.; Mercier, P.; Carlson, E.; Slupsky, C. M. Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal. Chem. 2006, 78 (13), 4430-4442.
39. Cattaneo, E.; Zuccato, C.; Tartari, M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6 (12), 919-930.
40. Nicoli, F.; Vion-Dury, J.; Maloteaux, J. M.; Delwaide, C.; Confort-Gouny, S.; Sciaky, M.; Cozzone, P. J. CSF and serum metabolic profile of patients with Huntington's chorea: a study by high resolution proton NMR spectroscopy and HPLC. Neurosci. Lett. 1993, 154 (1-2), 47-51.
41. 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res. 2005, 1031 (1), 82-89.
42. Taylor-Robinson, S. D.; Weeks, R. A.; Bryant, D. J.; Sargentoni, J.; Marcus, C. D.; Harding, A. E.; Brooks, D. J. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov. Disord. 1996, 11 (2), 167-173.
43. Underwood, B. R.; Broadhurst, D.; Dunn, W. B.; Ellis, D. I.; Michell, A. W.; Vacher, C.; Mosedale, D. E.; Kell, D. B.; Barker, R. A.; Grainger, D. J.; Rubinsztein, D. C. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006, 129 (4), 877-886.
44. Jenkins, B. G.; Andreassen, O. A.; Dedeoglu, A.; Leavitt, B.; Hayden, M.; Borchelt, D.; Ross, C. A.; Ferrante, R. J.; Beal, M. F. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J. Neurochem. 2005, 95 (2), 553-562.
45. Jenkins, B. G.; Klivenyi, P.; Kustermann, E.; Andreassen, O. A.; Ferrante, R. J.; Rosen, B. R.; Beal, M. F. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 2000, 74 (5), 2108-2119.
46. Tkac, I.; Dubinsky, J. M.; Keene, C. D.; Gruetter, R.; Low, W. C. Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy. J. Neurochem. 2007, 100 (5), 1397-1406.
47. 1H NMR spectroscopy. J. Proteome Res. 2006, 5 (3), 483-492.
48. Kaddurah-Daouk, R.; Krishnan, K. R. R. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 2008, 34 (1), 173-186.
49. Gowda, G. N.; Zhang, S.; Gu, H.; Asiago, V.; Shanaiah, N.; Raftery, D. Metabolomics-based methods for early disease diagnostics. Expert Rev. Mol. Diagn. 2008, 8 (5), 617-633.
50. Powers, R. NMR metabolomics and drug discovery. Magn. Reson. Chem. 2009, DOI: 10.1002/mrc.2461.
51. Dunckley, T.; Coon, K. D.; Stephan, D. A. Discovery and development of biomarkers of neurological disease. Drug Discovery Today 2005, 10 (5), 326-334.
52. Steuer, R. Review: On the analysis and interpretation of correlations in metabolomic data. Briefings Bioinf. 2006, 7 (2), 151-158.
53. MacDonald, M. E.; Ambrose, C. M.; Duyao, M. P.; Myers, R. H.; Lin, C.; Srinidhi, L.; Barnes, G.; Taylor, S. A.; James, M.; Groot, N.; MacFarlane, H.; Jenkins, B.; Anderson, M. A.; Wexler, N. S.; Gusella, J. F.; Bates, G. P.; Baxendale, S.; Hummerich, H.; Kirby, S.; North, M.; Youngman, S.; Mott, R.; Zehetner, G.; Sedlacek, Z.; Poustka, A.; Frischauf, A.-M.; Lehrach, H.; Buckler, A. J.; Church, D.; Doucette-Stamm, L.; O'Donovan, M. C.; Riba-Ramirez, L.; Shah, M.; Stanton, V. P.; Strobel, S. A.; Draths, K. M.; Wales, J. L.; Dervan, P.; Housman, D. E.; Altherr, M.; Shiang, R.; Thompson, L.; Fielder, T.; Wasmuth, J. J.; Tagle, D.; Valdes, J.; Elmer, L.; Allard, M.; Castilla, L.; Swaroop, M.; Blanchard, K.; Collins, F. S.; Snell, R.; Holloway, T.; Gillespie, K.; Datson, N.; Shaw, D.; Harper, P. S. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72 (6), 971-983.
54. Fecke, W.; Gianfriddo, M.; Gaviraghi, G.; Terstappen, G. C.; Heitz, F. Small molecule drug discovery for Huntington's Disease. Drug Discovery Today 2009, 14 (9-10), 453-464.